Indivior (NASDAQ:INDV) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Indivior (NASDAQ:INDV) from a buy rating to a strong-buy rating in a research note published on Saturday.

Separately, Piper Sandler reduced their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $15.00.

Indivior Price Performance

INDV stock opened at $13.95 on Friday. The stock has a market capitalization of $1.93 billion, a P/E ratio of -45.00 and a beta of 0.66. The business has a 50-day moving average of $11.77 and a 200-day moving average of $11.05. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $16.69.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analysts’ expectations of $240.13 million. Indivior had a negative return on equity of 97.29% and a negative net margin of 4.02%. Equities analysts expect that Indivior will post 1.22 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INDV. VELA Investment Management LLC boosted its position in Indivior by 45.5% during the fourth quarter. VELA Investment Management LLC now owns 179,659 shares of the company’s stock valued at $2,264,000 after purchasing an additional 56,224 shares during the last quarter. Clark Estates Inc. NY boosted its position in Indivior by 1.3% during the fourth quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock valued at $3,199,000 after purchasing an additional 3,300 shares during the last quarter. Amundi boosted its position in Indivior by 12.2% during the fourth quarter. Amundi now owns 174,434 shares of the company’s stock valued at $2,109,000 after purchasing an additional 19,010 shares during the last quarter. Kazazian Asset Management LLC acquired a new position in Indivior during the fourth quarter valued at approximately $1,706,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Indivior during the fourth quarter valued at approximately $978,000. 60.33% of the stock is owned by institutional investors and hedge funds.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.